Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | ALPG | P10696 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.48 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19014920 | 0.94 | EPHX1 (0.48) | NPSR1ALDH1A1ALPGPPARGHTT | |
| SCHEMBL18697735 | 0.92 | EPHX1 (0.52) | NPSR1ALDH1A1TSHREPHX1LMNA | |
| SCHEMBL23843974 | 0.92 | EPHX1 (0.52) | NPSR1ALDH1A1TSHREPHX1LMNA | |
| SCHEMBL10149758 | 0.92 | EPHX1 (0.52) | NPSR1ALDH1A1TSHREPHX1LMNA | |
| SCHEMBL14621493 | 0.88 | ALDH1A1 (0.39) | NPSR1ALDH1A1ALPGPPARGHTT | |
| SCHEMBL18510055 | 0.83 | ALDH1A1 (0.52) | NPSR1ALDH1A1ALPGPPARGHTT | |
| SCHEMBL18510017 | 0.83 | ALDH1A1 (0.52) | NPSR1ALDH1A1ALPGPPARGHTT | |
| SCHEMBL807264 | 0.82 | ALDH1A1 (0.50) | NPSR1ALDH1A1ALPGPPARGHTT | |
| SCHEMBL14304682 | 0.82 | ALDH1A1 (0.50) | NPSR1ALDH1A1ALPGPPARGHTT | |
| SCHEMBL16155384 | 0.80 | ALDH1A1 (0.48) | NPSR1ALDH1A1ALPGPPARGHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030903-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20210292348-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2021-09-23 | — | — | US | disclosed |
| US-20140066398-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR, AB (SE) | 2014-03-06 | — | — | US | disclosed |
| US-20130143835-A1 | HCV Polymerase Inhibitors | MEDIVIR AB (SE) | 2013-06-06 | — | — | US | disclosed |
| US-20090291922-A1 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-20070190523-A1 | Method and compositions for identifying anti-hiv therapeutic compounds | GILEAD SCIENCES, INC. | 2007-08-16 | — | — | US | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
| WO-2007002912-A2 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002808-A1 | ANTI-NONMELANOMA CARCINOMA COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030903-B2 | Antiviral compounds | EIF2AK2, MAVS, DUT | NPSR1 3651/4885ALDH1A1 1761/4885ALPG 3611/4885 |
| US-20130143835-A1 | HCV Polymerase Inhibitors | POLI, HAVCR2, EIF2AK2 | NPSR1 3871/4885ALDH1A1 362/4885ALPG 4032/4885 |
| US-20210292348-A1 | ANTIVIRAL COMPOUNDS | EIF2AK2, MAVS, DUT | NPSR1 3651/4885ALDH1A1 1761/4885ALPG 3611/4885 |
| US-20140066398-A1 | HCV POLYMERASE INHIBITORS | POLI, HAVCR2, EIF2AK2 | NPSR1 3871/4885ALDH1A1 362/4885ALPG 4032/4885 |
| US-20090291922-A1 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | CCNY, CCNO, CCNB3 | NPSR1 465/4885ALDH1A1 3836/4885ALPG 1093/4885 |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | PPA1, PNP, PPME1 | NPSR1 4160/4885ALDH1A1 3337/4885ALPG 1820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.